| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PPAP2C |
| Uniprot No | O43688 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-288aa |
| 氨基酸序列 | MQRRWVFVLLDVLCLLVASLPFAILTLVNAPYKRGFYCGDDSIRYPYRPDTITHGLMAGVTITATVILVSAGEAYLVYTDRLYSRSDFNNYVAAVYKVLGTFLFGAAVSQSLTDLAKYMIGRLRPNFLAVCDPDWSRVNCSVYVQLEKVCRGNPADVTEARLSFYSGHSSFGMYCMVFLALYVQARLCWKWARLLRPTVQFFLVAFALYVGYTRVSDYKHHWSDVLVGLLQGALVAALTVCYISDFFKARPPQHCLKEEELERKPSLSLTLTLGEADHNHYGYPHSSS |
| 预测分子量 | 32,5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PPAP2C重组蛋白的3篇参考文献及其摘要概览：
---
1. **文献名称**: *"Recombinant PPAP2C/LPP3 regulates Wnt/β-catenin signaling via lipid phosphate phosphatase activity"*
**作者**: Escalante-Alcalde D, et al.
**摘要**: 本研究利用重组PPAP2C蛋白(人源LPP3)探究其通过水解脂质信号分子(如溶血磷脂酸)调控Wnt/β-catenin通路的机制。实验表明，重组PPAP2C的酶活性可抑制β-catenin核转位，提示其在胚胎发育和癌症中的潜在作用。
2. **文献名称**: *"Expression and functional characterization of human PPAP2C in lipid metabolism"*
**作者**: Tang X, Morris AJ.
**摘要**: 通过大肠杆菌系统表达并纯化重组人PPAP2C蛋白，分析其对多种脂质磷酸底物(如鞘氨醇-1-磷酸)的水解活性。结果表明，PPAP2C在调节细胞外脂质信号及动脉粥样硬化相关代谢途径中起关键作用。
3. **文献名称**: *"PPAP2C interacts with VEGFR2 to modulate angiogenesis via dephosphorylation of lysophosphatidic acid"*
**作者**: Lee S, et al.
**摘要**: 研究利用HEK293细胞表达的重组PPAP2C蛋白，发现其与血管内皮生长因子受体2(VEGFR2)结合，并通过降解溶血磷脂酸(LPA)抑制血管生成。该发现为靶向PPAP2C的抗肿瘤治疗提供了理论依据。
---
**备注**：若需获取具体文献，建议通过PubMed或Google Scholar以上述标题/作者为关键词检索全文。部分研究可能以PPAP2C的别名“LPP3”(Lipid Phosphate Phosphatase 3)命名。
**Background of PPAP2C Recombinant Protein**
The PPAP2C (Phosphatidic Acid Phosphatase Type 2C) protein, also known as lipid phosphate phosphatase 3 (LPP3), is a member of the phosphatidic acid phosphatase family. It plays a critical role in lipid metabolism and cellular signaling by catalyzing the dephosphorylation of lipid phosphates, such as phosphatidic acid (PA) and lysophosphatidic acid (LPA), to their corresponding diacylglycerols or monoacylglycerols. This enzymatic activity regulates the balance of bioactive lipids involved in diverse physiological processes, including cell proliferation, migration, and inflammation.
PPAP2C is implicated in several pathological conditions, such as cancer, cardiovascular diseases, and metabolic disorders. Its role in modulating lipid signaling pathways, particularly the LPA and sphingosine-1-phosphate (S1P) pathways, highlights its potential as a therapeutic target. For instance, aberrant PPAP2C expression has been linked to tumor progression and chemoresistance in cancers, while its regulatory effects on vascular development underscore its relevance in cardiovascular research.
Recombinant PPAP2C protein is produced using biotechnological platforms (e.g., bacterial, mammalian, or insect cell systems) to enable functional studies. This engineered protein retains catalytic activity and structural integrity, allowing researchers to investigate its biochemical properties, substrate specificity, and interactions with signaling molecules. Applications include in vitro assays to screen inhibitors, mechanistic studies of lipid-mediated pathways, and exploration of its therapeutic potential in disease models.
Current research focuses on elucidating PPAP2C’s role in disease mechanisms and its utility as a biomarker or drug target. The development of recombinant PPAP2C has accelerated translational studies, offering insights into lipid metabolism dysregulation and paving the way for novel therapeutic strategies.
×
